Depletion of skeletal muscle protein mainly results from enhanced protein breakdown, caused by activation of proteolytic systems such as the Ca2?-dependent and the ATP-ubiquitin-dependent ones. In the last few years, enhanced expression and bioactivity of myostatin have been reported in several pathologies characterized by marked skeletal muscle depletion. More recently, high myostatin levels have been associated with glucocorticoidinduced hypercatabolism. The search for therapeutical strategies aimed at preventing/correcting protein hypercatabolism has been directed to inhibit humoral mediators known for their pro-catabolic action, such as TNFa. The present study has been aimed to investigate the involvement of TNFa in the regulation of both myostatin expression and intracellular protein catabolism, and the possibility to interfere with such modulations by means of amino acid supplementation. For this purpose, C2C12 myotubes exposed to TNFa in the presence or in the absence of amino acid (glutamine or leucine) supplementation have been used. Myotube treatment with TNFa leads to both hyperexpression of the muscle-specific ubiquitin ligase atrogin-1, and enhanced activity of the Ca2?- dependent proteolytic system. These changes are associated with increased myostatin expression. Glutamine supplementation effectively prevents TNFa-induced muscle protein loss and restores normal myostatin levels. The results shown in the present study indicate a direct involvement of TNFa in the onset of myotube protein loss and in the perturbation of myostatin-dependent signaling. In addition, the protective effect exerted by glutamine suggests that amino acid supplementation could represent a possible strategy to improve muscle mass.
Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by Tumor Necrosis Factor-alpha
PENNA, FABIO;MINERO, Valerio Giacomo;COSTAMAGNA, DOMIZIANA;BONELLI, Gabriella;BACCINO, Francesco Maria;COSTELLI, Paola
2011-01-01
Abstract
Depletion of skeletal muscle protein mainly results from enhanced protein breakdown, caused by activation of proteolytic systems such as the Ca2?-dependent and the ATP-ubiquitin-dependent ones. In the last few years, enhanced expression and bioactivity of myostatin have been reported in several pathologies characterized by marked skeletal muscle depletion. More recently, high myostatin levels have been associated with glucocorticoidinduced hypercatabolism. The search for therapeutical strategies aimed at preventing/correcting protein hypercatabolism has been directed to inhibit humoral mediators known for their pro-catabolic action, such as TNFa. The present study has been aimed to investigate the involvement of TNFa in the regulation of both myostatin expression and intracellular protein catabolism, and the possibility to interfere with such modulations by means of amino acid supplementation. For this purpose, C2C12 myotubes exposed to TNFa in the presence or in the absence of amino acid (glutamine or leucine) supplementation have been used. Myotube treatment with TNFa leads to both hyperexpression of the muscle-specific ubiquitin ligase atrogin-1, and enhanced activity of the Ca2?- dependent proteolytic system. These changes are associated with increased myostatin expression. Glutamine supplementation effectively prevents TNFa-induced muscle protein loss and restores normal myostatin levels. The results shown in the present study indicate a direct involvement of TNFa in the onset of myotube protein loss and in the perturbation of myostatin-dependent signaling. In addition, the protective effect exerted by glutamine suggests that amino acid supplementation could represent a possible strategy to improve muscle mass.File | Dimensione | Formato | |
---|---|---|---|
Post-print-open-access-2014.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
554.26 kB
Formato
Adobe PDF
|
554.26 kB | Adobe PDF | Visualizza/Apri |
Amino-Acids-2011.pdf
Accesso riservato
Descrizione: articolo principale
Tipo di file:
PDF EDITORIALE
Dimensione
658.58 kB
Formato
Adobe PDF
|
658.58 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.